Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BAROS vs ORPHENGESIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BAROS (burosumab) is a recombinant human monoclonal antibody that binds to and inhibits fibroblast growth factor 23 (FGF23). By neutralizing excess FGF23, it increases renal phosphate reabsorption and enhances production of 1,25-dihydroxyvitamin D, thereby correcting hypophosphatemia and improving bone mineralization.
ORPHENGESIC (oxycodone/naloxone) is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naloxone). Oxycodone acts primarily on mu-opioid receptors in the CNS to produce analgesia; naloxone, at oral doses, has low systemic bioavailability but antagonizes opioid effects on gut opioid receptors to reduce constipation.
Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older,Treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized
Management of moderate to severe pain requiring around-the-clock opioid therapy in patients who have failed alternative treatments,Opioid-induced constipation (off-label use of combination due to naloxone component)
None established.
10 mg oral every 4-6 hours as needed; maximum 60 mg per day.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30 hours in severe cases).
3-4 hours in adults; prolonged in hepatic impairment (up to 6-8 hours) and elderly (up to 5 hours). Requires dose adjustment in cirrhosis.
Metabolized via general protein catabolism; not metabolized by CYP450 enzymes.
Oxycodone is primarily metabolized via CYP3A4 and CYP2D6 to noroxycodone (major) and oxymorphone (minor). Naloxone is extensively metabolized in the liver by UDP-glucuronosyltransferases (UGT2B7) and also by CYP3A4 to naloxone-3-glucuronide.
Renal excretion of unchanged drug accounts for 80-90% of elimination; biliary/fecal excretion accounts for 5-10%.
Renal: 70-80% as conjugates; fecal: 10-20% via biliary elimination; <5% unchanged drug in urine.
85-90% bound to albumin.
90-95% primarily to alpha-1-acid glycoprotein and albumin.
0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
2.5-3.5 L/kg; large Vd indicates extensive tissue distribution, including CNS.
Oral: 60-80% (first-pass metabolism reduces bioavailability).
Oral: 40-60% (first-pass effect); Sublingual: 15-25%; Intramuscular: 70-80%; Rectal: 40-60%; Intravenous: 100%.
No data available.
GFR 30-50 m L/min: 5 mg every 6 hours; GFR 15-29 m L/min: 5 mg every 8 hours; GFR <15 m L/min: 5 mg every 12 hours; avoid in dialysis.
No data available.
Child-Pugh A: 5 mg every 6 hours; Child-Pugh B: 5 mg every 8 hours; Child-Pugh C: not recommended.
No data available.
6-12 years: 0.5 mg/kg oral every 6 hours; 12-18 years: 5-10 mg oral every 6 hours; maximum 60 mg/day.
No data available.
Initiate at 5 mg oral every 6 hours; titrate cautiously due to increased sensitivity and risk of falls; maximum 30 mg per day.
None
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISKS OF TREATMENT FOR OPIOID USE DISORDER (if applicable).
Hyperphosphatemia and risk of nephrocalcinosis/nephrolithiasis: monitor serum phosphorus and renal function,Severe hypersensitivity reactions including anaphylaxis,Potential for injection site reactions,Risk of hyperphosphatemia in patients with severe renal impairment,May increase risk of infections; avoid live vaccines during treatment
Risk of addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use of benzodiazepines or other CNS depressants,Adrenal insufficiency,Severe hypotension,Seizures,Chronic use may cause physical dependence and withdrawal if abruptly discontinued
Concomitant use with oral phosphate and active vitamin D analogs (e.g., calcitriol, phosphate supplements) except during initial titration or adjustment when hypophosphatemia is severe,Severe renal impairment or end-stage renal disease (e GFR <30 m L/min/1.73 m²),Known hypersensitivity to burosumab or any excipients
Hypersensitivity to oxycodone, naloxone, or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
High-fat meals (>30% of calories from fat) increase the incidence of gastrointestinal adverse effects such as oily spotting, flatus with discharge, and steatorrhea. Dietary fat intake should be distributed over three main meals. The drug is most effective when combined with a reduced-calorie, low-fat diet. Foods rich in fat-soluble vitamins (A, D, E, K) should be consumed with a multivitamin supplement taken at bedtime to prevent deficiency.
Avoid alcohol. No specific food restrictions, but high-fat meals may delay absorption.
BAROS is contraindicated in pregnancy due to teratogenicity. First trimester: high risk of cardiac, CNS, and skeletal defects. Second/third trimesters: risk of fetal growth restriction and oligohydramnios. Animal studies show dose-dependent embryotoxicity. Human data limited but indicates significant risk.
Orphengesic (orphenadrine citrate, aspirin, and caffeine) is contraindicated in pregnancy, especially during the third trimester, due to aspirin's association with premature closure of the ductus arteriosus, oligohydramnios, and increased risk of fetal intracranial hemorrhage. First trimester aspirin exposure may increase risk of gastroschisis and other malformations. Orphenadrine has limited data but anticholinergic effects could potentially cause fetal tachycardia or meconium ileus. Caffeine at high doses is associated with low birth weight and miscarriage.
Excreted in breast milk; M/P ratio = 1.2. Avoid breastfeeding due to potential for infant toxicity. If unavoidable, monitor infant for drowsiness and poor feeding.
Orphengesic is not recommended during breastfeeding. Aspirin excretes into breast milk and may cause Reye's syndrome or platelet dysfunction in the infant. Orphenadrine is excreted in small amounts; its anticholinergic effects may reduce milk production or cause infant sedation. Caffeine levels in milk are low but may cause irritability. M/P ratio for aspirin is ~0.6; data for orphenadrine and caffeine are insufficient.
Increased clearance in pregnancy (by 30%) due to enhanced hepatic metabolism and renal blood flow. Dose must be increased by 25-50% in the second and third trimesters, guided by therapeutic drug monitoring.
No established safe dose in pregnancy; use is contraindicated. Physiological changes (increased plasma volume, renal clearance) do not permit safe dosing due to teratogenicity. If unavoidable, lowest effective dose and shortest duration, but aspirin should be <100 mg/day; orphenadrine and caffeine avoid.
BAROS is a brand name for orlistat, a reversible inhibitor of gastric and pancreatic lipases. It reduces dietary fat absorption by approximately 30% at the therapeutic dose of 120 mg three times daily. Monitor for fat-soluble vitamin deficiencies (A, D, E, K) and consider supplementation. Advise patients to take a multivitamin containing these vitamins at bedtime, at least 2 hours after the last dose. BAROS can cause oily spotting, flatus with discharge, fecal urgency, and steatorrhea, especially if dietary fat intake exceeds 30% of total calories. Contraindicated in chronic malabsorption syndrome and cholestasis. Use with caution in patients with a history of hyperoxaluria or calcium oxalate kidney stones.
ORPHENGESIC contains orphenadrine, a centrally acting muscle relaxant with anticholinergic properties. Avoid in patients with glaucoma, urinary retention, or myasthenia gravis. Onset within 1 hour; monitor for sedation and anticholinergic effects. Not recommended in elderly due to fall risk.
Take BAROS with each main meal containing fat, up to three times daily.,If you miss a meal or eat a fat-free meal, skip the dose.,Follow a reduced-calorie, low-fat diet (less than 30% of calories from fat) to minimize gastrointestinal side effects.,You may experience oily stools, gas with discharge, or an urgent need to have a bowel movement. These effects are common and often improve with time.,Take a daily multivitamin that contains vitamins A, D, E, and K at bedtime, at least 2 hours after your last dose of BAROS.,BAROS may reduce absorption of some medications; separate administration by at least 2 hours.,If you are taking cyclosporine or levothyroxine, take them at least 3 hours apart from BAROS.,Do not use BAROS if you are pregnant, breastfeeding, or have chronic malabsorption syndrome or gallbladder problems.,Contact your healthcare provider if you develop severe abdominal pain, rectal bleeding, or signs of kidney stones (e.g., pain during urination, back pain).
May cause drowsiness or dizziness; avoid driving or operating heavy machinery.,Avoid alcohol and other CNS depressants.,Report blurred vision, difficulty urinating, or rapid heartbeat to your doctor.,Swallow tablets whole; do not crush or chew.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BAROS vs ORPHENGESIC, answered by our medical review team.
BAROS is a Stimulant Laxative that works by BAROS (burosumab) is a recombinant human monoclonal antibody that binds to and inhibits fibroblast growth factor 23 (FGF23). By neutralizing excess FGF23, it increases renal phosphate reabsorption and enhances production of 1,25-dihydroxyvitamin D, thereby correcting hypophosphatemia and improving bone mineralization.. ORPHENGESIC is a Muscle relaxant combination that works by ORPHENGESIC (oxycodone/naloxone) is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naloxone). Oxycodone acts primarily on mu-opioid receptors in the CNS to produce analgesia; naloxone, at oral doses, has low systemic bioavailability but antagonizes opioid effects on gut opioid receptors to reduce constipation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BAROS and ORPHENGESIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BAROS is: None established.. The standard adult dose of ORPHENGESIC is: 10 mg oral every 4-6 hours as needed; maximum 60 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BAROS and ORPHENGESIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BAROS is classified as Category C. BAROS is contraindicated in pregnancy due to teratogenicity. First trimester: high risk of cardiac, CNS, and skeletal defects. Second/third trimesters: risk of fetal growth restric. ORPHENGESIC is classified as Category C. Orphengesic (orphenadrine citrate, aspirin, and caffeine) is contraindicated in pregnancy, especially during the third trimester, due to aspirin's association with premature closur. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.